MOTS-c Peptide Improves Muscle Energy Production Efficiency

The mitochondria-derived peptide MOTS-c improved intrinsic muscle mitochondrial bioenergetic capacity and efficiency, positioning it as a potential therapeutic for aging and metabolic dysfunction.

Gudiksen, Anders et al.·Free radical biology & medicine·2026·
RPEP-152352026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

MOTS-c treatment improved intrinsic muscle mitochondrial bioenergetic capacity and energy production efficiency, with potential therapeutic applications for aging and metabolic disease.

Key Numbers

How They Did This

Assessment of muscle mitochondrial bioenergetics after MOTS-c treatment, measuring respiratory capacity, coupling efficiency, and ATP production.

Why This Research Matters

Mitochondrial dysfunction underlies aging, diabetes, and many chronic diseases. A peptide that directly improves mitochondrial performance could address these conditions at their root cause.

The Bigger Picture

MOTS-c represents a new therapeutic class: mitochondria-derived peptides that can be administered to improve cellular energy production, opening possibilities for treating age-related decline.

What This Study Doesn't Tell Us

Preclinical evidence. Optimal dosing, route, and duration for therapeutic use not established. Long-term effects unknown.

Questions This Raises

  • ?Could MOTS-c supplementation slow age-related muscle decline?
  • ?What is the optimal route of MOTS-c administration for therapeutic benefit?
  • ?Does MOTS-c have effects on non-muscle tissues?

Trust & Context

Key Stat:
Peptide from mitochondria MOTS-c is made by mitochondria themselves and can improve how muscles produce energy when administered as a therapy
Evidence Grade:
Preclinical mechanistic study. Novel peptide biology with therapeutic implications needing clinical development.
Study Age:
Published in 2025.
Original Title:
MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.
Published In:
Free radical biology & medicine, 246, 682-696 (2026)
Database ID:
RPEP-15235

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What is MOTS-c?

MOTS-c is a small peptide produced by mitochondria — the energy factories in our cells. When given as a treatment, it improves how muscles produce energy, potentially fighting age-related decline.

Could MOTS-c slow aging?

Possibly. By improving mitochondrial function in muscles, MOTS-c addresses one of the fundamental processes of aging. However, this is still in early research stages and not available as a therapy.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15235·https://rethinkpeptides.com/research/RPEP-15235

APA

Gudiksen, Anders; Hansen, Camilla Collin; van der Stede, Thibaux; Daugaard, Amalie Hertz; Schmidt, Josefine H; Ringholm, Stine; Merimi, Manal; Al-Obaidi, Fatima Raad; Kristoffersen, Amanda Takamiya; Zole, Egija; Regenberg, Birgitte; Kjøbsted, Rasmus; Wojtaszewski, Jørgen; Hellsten, Ylva; Pilegaard, Henriette. (2026). MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.. Free radical biology & medicine, 246, 682-696. https://doi.org/10.1016/j.freeradbiomed.2026.01.002

MLA

Gudiksen, Anders, et al. "MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.." Free radical biology & medicine, 2026. https://doi.org/10.1016/j.freeradbiomed.2026.01.002

RethinkPeptides

RethinkPeptides Research Database. "MOTS-c improves intrinsic muscle mitochondrial bioenergetic ..." RPEP-15235. Retrieved from https://rethinkpeptides.com/research/gudiksen-2026-motsc-improves-intrinsic-muscle

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.